{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:25:58Z","timestamp":1785288358891,"version":"3.55.0"},"reference-count":91,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Homologous recombination (HR) is a DNA repair pathway that is deficient in 50% of high-grade serous ovarian carcinomas (HGSOC). Deficient HR (DHR) constitutes a therapeutic opportunity for these patients, thanks to poly (ADP-ribose) polymerases (PARP) inhibitors (PARPi; olaparib, niraparib, and rucaparib are already commercialized). Although initially, PARPi were developed for patients with BRCA1\/2 mutations, robust clinical data have shown their benefit in a broader population without DHR. This breakthrough in daily practice has raised several questions that necessitate further research: How can populations that will most benefit from PARPi be selected? At which stage of ovarian cancer should PARPi be used? Which strategies are reasonable to overcome PARPi resistance? In this paper, we present a summary of the literature and discuss the present clinical research involving PARPi (after reviewing ClinicalTrials.gov) from a translational perspective. Research into the functional biomarkers of DHR and clinical trials testing PARPi benefits as first-line setting or rechallenge are currently ongoing. Additionally, in the clinical setting, only secondary restoring mutations of BRCA1\/2 have been identified as events inducing resistance to PARPi. The clinical frequency of this and other mechanisms that have been described in preclinics is unknown. It is of great importance to study mechanisms of resistance to PARPi to guide the clinical development of drug combinations.<\/jats:p>","DOI":"10.3390\/ijms19103249","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T10:08:02Z","timestamp":1539943682000},"page":"3249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-8115","authenticated-orcid":false,"given":"Margarita","family":"Romeo","sequence":"first","affiliation":[{"name":"Medical Oncology Department, B-ARGO Group, Institut Catal\u00e0 d\u2019Oncologia Badalona, Carretera del Canyet s\/n, 08916 Badalona, Spain"},{"name":"Campus de la UAB, Universitat Aut\u00f3noma de Barcelona, Pla\u00e7a C\u00edvica, 08193 Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Pardo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, B-ARGO Group, Institut Catal\u00e0 d\u2019Oncologia Badalona, Carretera del Canyet s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3937-8794","authenticated-orcid":false,"given":"Anna","family":"Mart\u00ednez-Card\u00fas","sequence":"additional","affiliation":[{"name":"Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP), B-ARGO Group, Carretera del Canyet s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4501-7100","authenticated-orcid":false,"given":"Eva","family":"Mart\u00ednez-Balibrea","sequence":"additional","affiliation":[{"name":"Program against Cancer Therapeutic Resistance (ProCURE), Institut Catal\u00e0 d\u2019Oncologia Badalona, Program for Predictive and Personalized Cancer Medicine (PMPPC), Health Sciences Research Institute Germans Trias i Pujo (IGTP), Carretera de Can Ruti, Cam\u00ed de les Escoles s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Quiroga","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, B-ARGO Group, Institut Catal\u00e0 d\u2019Oncologia Badalona, Carretera del Canyet s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Mart\u00ednez-Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Gynecology Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Sol\u00e9","sequence":"additional","affiliation":[{"name":"Institut de Recerca contra la Leucemia Josep Carreras, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Margel\u00ed","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, B-ARGO Group, Institut Catal\u00e0 d\u2019Oncologia Badalona, Carretera del Canyet s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Mes\u00eda","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, B-ARGO Group, Institut Catal\u00e0 d\u2019Oncologia Badalona, Carretera del Canyet s\/n, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Opinion: Hallmarks of \u201cBRCAness\u201d in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc1431","article-title":"BRCA1 and BRCA2: 1994 and beyond","volume":"4","author":"Narod","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nrm2831","article-title":"BRCA1 and its toolbox for the maintenance of genome integrity","volume":"11","author":"Huen","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2007.11.3902","article-title":"Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway","volume":"26","author":"Weberpals","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association Between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cell.2011.03.020","article-title":"Genetic interactions in cancer progression and treatment","volume":"145","author":"Ashworth","year":"2011","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/cas.13530","article-title":"Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1\/2-mutated cancer","volume":"109","author":"Sunada","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly (ADP-ribose) Polymerase Inhibitor Olaparib in Patients with BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer: A Proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_16","unstructured":"(2018, September 27). U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/lab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","unstructured":"(2018, September 27). European Medicines Agency. Available online: http:\/\/www.ema.europa.eu\/ema\/index."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Ledermann","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"ENGOT-OV16\/NOVA Investigators Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"Cancer Therapy: Clinical A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tan, D.S.P., and Kaye, S.B. (2015). Chemotherapy for Patients with BRCA1 and BRCA2\u2013Mutated Ovarian Cancer: Same or Different?. Am. Soc. Clin. Oncol. Educ. Book, 114\u2013121.","DOI":"10.14694\/EdBook_AM.2015.35.114"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for Homologous Recombination Deficiency in Cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","unstructured":"(2018, September 27). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1200\/JCO.2018.36.15_suppl.5545","article-title":"Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3","volume":"36","author":"Oaknin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1200\/JCO.2018.36.15_suppl.5563","article-title":"Locus-specific loss of heterozygosity (LOH) in BRCA1\/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials","volume":"36","author":"Timms","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","article-title":"BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy","volume":"13","author":"Quinn","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: A Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jnci\/djs177","article-title":"A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer Treated with Platinum-Based Chemotherapy","volume":"104","author":"Kang","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1470-2045(16)30621-0","article-title":"Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?","volume":"18","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6159","DOI":"10.1158\/1078-0432.CCR-10-1027","article-title":"A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer","volume":"16","author":"Graeser","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/path.1625","article-title":"Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression","volume":"204","author":"Gonzalez","year":"2004","journal-title":"J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mrfmmm.2005.01.019","article-title":"Analysis of ionizing radiation-induced foci of DNA damage repair proteins","volume":"574","author":"Cervelli","year":"2005","journal-title":"Mutat. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole\u2013genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13669","DOI":"10.1074\/jbc.M110.213728","article-title":"The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection","volume":"286","author":"Coleman","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nsmb.1831","article-title":"53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers","volume":"17","author":"Bouwman","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in BRCA1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/nsmb.2702","article-title":"JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks","volume":"20","author":"Watanabe","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature14328","article-title":"REV7 counteracts DNA double-strand break resection and affects PARP inhibition","volume":"521","author":"Xu","year":"2015","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature14216","article-title":"MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5\u2032 end resection","volume":"521","author":"Boersma","year":"2015","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.molcel.2013.01.002","article-title":"RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection","volume":"49","author":"Chapman","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.celrep.2016.05.031","article-title":"FANCD2 Maintains Fork Stability in BRCA1\/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair","volume":"15","author":"Kais","year":"2016","journal-title":"Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7150\/ijbs.17240","article-title":"Reverse the resistance to PARP inhibitors","volume":"13","author":"Kim","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.2147\/OTT.S139336","article-title":"Current status of poly(ADP-ribose) polymerase inhibitors and future directions","volume":"10","author":"Ohmoto","year":"2017","journal-title":"Onco. Targets. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"mdw697","DOI":"10.1093\/annonc\/mdw697","article-title":"PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: Does a development pathway forward exist?","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/jco.2015.33.15_suppl.5573","article-title":"A Phase Ib\/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients","volume":"33","author":"Rivkin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1200\/jco.2015.33.15_suppl.5507","article-title":"A phase I study of continuous veliparib in combination with IV carboplatin\/paclitaxel or IV\/IP paclitaxel\/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"33","author":"Brady","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2015.11.024","article-title":"A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"140","author":"Landrum","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1200\/JCO.2017.35.15_suppl.5572","article-title":"A phase I dose-escalation study of intraperitoneal (IP) cisplatin, IV\/IP paclitaxel, IV bevacizumab, and oral olaparib for newly diagnosed adenxal carcinoma","volume":"35","author":"Konner","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","article-title":"Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer","volume":"21","author":"Kummar","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/jpet.113.210146","article-title":"Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition","volume":"349","author":"Murai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1158\/1078-0432.CCR-15-0652","article-title":"Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors","volume":"22","author":"LoRusso","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12964-017-0195-9","article-title":"DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway","volume":"15","author":"Bhattacharjee","year":"2017","journal-title":"Cell Commun. Signal."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/iub.1696","article-title":"Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics","volume":"69","author":"Bhattacharjee","year":"2017","journal-title":"IUBMB Life"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neo.2014.04.003","article-title":"VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2","volume":"16","author":"Lim","year":"2014","journal-title":"Neoplasia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","article-title":"Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells","volume":"24","author":"Bindra","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Huang, F., and Mazin, A.V. (2014). A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100993"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.chembiol.2015.10.003","article-title":"Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers","volume":"22","author":"Chandramouly","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Sullivan, K., Cramer-Morales, K., McElroy, D.L., Ostrov, D.A., Haas, K., Childers, W., Hromas, R., and Skorski, T. (2016). Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147230"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase \u03b8 promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Gong","year":"2015","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","article-title":"Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer","volume":"2","author":"Juvekar","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/annonc\/mdw672","article-title":"Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer","volume":"28","author":"Matulonis","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"CT323","DOI":"10.1158\/1538-7445.AM2015-CT323","article-title":"Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients","volume":"75","author":"Michalarea","year":"2015","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 \u2212\/\u2212 murine model of ovarian cancer","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2018.36.15_suppl.106","article-title":"TTOPACIO\/Keynote-162 (NCT02657889): A phase 1\/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)\u2014Results from ROC cohort","volume":"36","author":"Konstantinopoulos","year":"2018","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:26:49Z","timestamp":1760196409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/10\/3249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":91,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"alternative-id":["ijms19103249"],"URL":"https:\/\/doi.org\/10.3390\/ijms19103249","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]}}}